Publication: The effect of interleukin-6 level at the time of hospitalisation on erectile functions in hospitalised patients with COVID-19
dc.contributor.coauthor | Sivritepe, Ridvan | |
dc.contributor.coauthor | Basat, Sema Ucak | |
dc.contributor.coauthor | Kucuk, Eyup Veli | |
dc.contributor.department | School of Medicine | |
dc.contributor.kuauthor | Baygül, Arzu Eden | |
dc.contributor.schoolcollegeinstitute | SCHOOL OF MEDICINE | |
dc.date.accessioned | 2024-11-09T23:19:49Z | |
dc.date.issued | 2022 | |
dc.description.abstract | We evaluated the relationship between erectile dysfunction (ED) and IL-6 levels in males with COVID-19. The study included 80 male patients aged 30-45 years who were hospitalised due to COVID-19. The International Index of Erectile Function (IIEF-5) questionnaire was used to assess erectile function. The IIEF-5 questionnaire was re-administered at a 3-month control visit after discharge, and the change score from baseline was recorded. The patients were divided into three groups according to the IIEF-5 score at 3 months as Group 1 (severe ED), Group 2 (moderate ED) and Group 3 (no ED), and into two groups according to IL-6 level at the time of admission as Group A (IL-6 <= 50 ng/ml) and Group B (IL-6 > 50 ng/ml). The change in the IIEF-5 score (p < .001) was significantly greater in Group B than in Group A. There was also significant difference in IL-6 between Group 1 and Group 2 (p = .008). The correlation analysis revealed a moderate correlation between IL-6 level and the change in IIEF-5 score and D-dimer level (r:0.529, p < .001) and a weak correlation between IL-6 level and FSH (r:0.309, p = .005). The present study suggests that elevated IL-6 levels in male patients hospitalised due to COVID-19 might be related to the risk of developing ED. | |
dc.description.indexedby | WOS | |
dc.description.indexedby | Scopus | |
dc.description.indexedby | PubMed | |
dc.description.issue | 1 | |
dc.description.openaccess | YES | |
dc.description.publisherscope | International | |
dc.description.sponsoredbyTubitakEu | N/A | |
dc.description.volume | 54 | |
dc.identifier.doi | 10.1111/and.14285 | |
dc.identifier.eissn | 1439-0272 | |
dc.identifier.issn | 0303-4569 | |
dc.identifier.scopus | 2-s2.0-85117472414 | |
dc.identifier.uri | https://doi.org/10.1111/and.14285 | |
dc.identifier.uri | https://hdl.handle.net/20.500.14288/10615 | |
dc.identifier.wos | 709918500001 | |
dc.keywords | COVID-19 | |
dc.keywords | Erectile dysfunction | |
dc.keywords | IIEF-5 | |
dc.keywords | Interleukin-6 | |
dc.language.iso | eng | |
dc.publisher | Wiley | |
dc.relation.ispartof | Andrologia | |
dc.subject | Andrology | |
dc.title | The effect of interleukin-6 level at the time of hospitalisation on erectile functions in hospitalised patients with COVID-19 | |
dc.type | Journal Article | |
dspace.entity.type | Publication | |
local.contributor.kuauthor | Baygül, Arzu Eden | |
local.publication.orgunit1 | SCHOOL OF MEDICINE | |
local.publication.orgunit2 | School of Medicine | |
relation.isOrgUnitOfPublication | d02929e1-2a70-44f0-ae17-7819f587bedd | |
relation.isOrgUnitOfPublication.latestForDiscovery | d02929e1-2a70-44f0-ae17-7819f587bedd | |
relation.isParentOrgUnitOfPublication | 17f2dc8e-6e54-4fa8-b5e0-d6415123a93e | |
relation.isParentOrgUnitOfPublication.latestForDiscovery | 17f2dc8e-6e54-4fa8-b5e0-d6415123a93e |